Vitality Watch

Dossier pubmed review 12-aug-2026
Narrative review or expert overview without new data

A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.

Key claim: Rejuvenating senescent mesenchymal stem cells with senolytics, SASP-targeted inhibitors, nanoplatforms/biomaterials, and physical exercise is a promising route to delay age-related bone loss and support bone regeneration.

Abstract

PURPOSE OF REVIEW: The purpose of this article is to emphasize the critical role aging and senescence plays on mesenchymal stem cell (MSC) functionality and its influence on bone health. This review also highlights recent advancements in strategies to rejuvenate senescent MSCs to aid in delaying or preventing age-related illnesses associated with bone loss. RECENT FINDINGS: Studies have expanded upon many established rejuvenation strategies including senolytic agents, drugs used to selectively eliminate senescent cells, and targeted inhibitors to the secretory profile of senescent cells. New routes for MSC rejuvenation including nanoplatform targets such as biomaterials, nanovesicles, and physical exercise are showing promise for future clinical applications. Ongoing clinical trials are progressing towards rejuvenation therapies that delay age-induced bone loss. This review provides an overview of the current research landscape into rejuvenation of senescent MSCs to combat bone loss due to age and highlights new platforms and strategies for rejuvenation that could have clinical relevance.

Why this matters

Rejuvenating senescent mesenchymal stem cells with senolytics, SASP-targeted inhibitors, nanoplatforms/biomaterials, and physical exercise is a promising route to delay age-related bone loss and support bone regeneration.

Source

Link

Briefing card

A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.
Stage: review · pubmed · 12-aug-2026

Rejuvenating senescent mesenchymal stem cells with senolytics, SASP-targeted inhibitors, nanoplatforms/biomaterials, and physical exercise is a promising route to delay age-related bone loss and support bone regeneration.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11914-026-00977-y

build build 880 · 2bcef25 · 2026-11-18